Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trafermin (FGF) Administration for Nasal Septal Perforation
jRCTs031220604Completed
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of trafermin in nasal septal perforation (NSP). Primary endpoint: Rate and details of adverse events. Started Mar 2023; status: completed.
02
Drugs
trafermin
03
Conditions
nasal septal perforation (NSP)
Beyond the preview
Go deeper on jRCTs031220604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220604.